drs. rini, wallis on a 5-year analysis of keynote-426 for advanced clear cell rcc
Published 1 year ago • 162 plays • Length 9:05Download video MP4
Download video MP3
Similar videos
-
1:59
dr rini on the background of a biomarker analysis of keynote-426 in rcc
-
1:18
dr rini on a biomarker analysis of keynote-426 using subtype clustering rcc
-
4:56
dr. rini discusses asco 2023 data in frontline rcc: clear and keynote-426 trials
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
1:15
dr. plimack on updated findings of the keynote-426 study in rcc
-
5:29
drs. lee, mckay on keynote-b61 for non-clear cell rcc
-
0:53
dr. rini on standards of care for advanced rcc
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
50:45
plasma cell dyscrasia and the kidney - fellow's core curriculum
-
19:31
adjuvant therapy in high risk renal cell carcinoma
-
5:09
recent advances in treating advanced kidney cancer
-
1:45
keynote-426: pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
-
1:34
dr. powles on rationale for keynote-426 in mrcc
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
13:35
asco gu 2020: dr. rini highlights key research efforts in kidney cancer
-
51:09
immunotherapy-based combinations for advanced/metastatic renal cell carcinoma: asco gu 2023
-
20:39
kidney cancer conference highlights from asco gu 2023
-
2:46
keynote-427 updates: first-line pembrolizumab monotherapy in patients with advanced clear cell r...
-
1:25
dr. tannir on the combination of sunitinib and temsirolimus for metastatic renal cell carcinoma
-
2:25
dr. tykodi on the keynote-427 trial with pembrolizumab in rcc
-
2:16
updated results from keynote-426 for metastatic kidney cancer